Mitomycin Medac (Mitomycin)

Mitomycin acts as an alkylating agent that creates covalent cross‑links between DNA strands. This interferes with DNA replication and transcription, leading to cell‑cycle arrest and programmed cell death, particularly in rapidly dividing urothelial cancer cells exposed to the drug.

The exact dose and schedule are determined by the prescribing physician based on the patient’s clinical condition, tumor characteristics, and renal function. Intravesical regimens typically involve a single‑dose instillation after transurethral resection, followed by additional courses as needed.

Mitomycin is classified as contraindicated in pregnancy because of its potential teratogenic effects. It should not be used by breastfeeding mothers, as the drug may be excreted in milk and could harm the infant. Consultation with a specialist is essential if exposure occurs.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to intravesical mitomycin is Bacillus Calmette‑Guérin (BCG) immunotherapy. While BCG stimulates an immune response, mitomycin provides direct cytotoxic activity. Choice of therapy depends on tumor grade, patient tolerance, prior treatment history, and institutional protocols.

Store Mitomycin Medac at temperatures below 25 °C, in its original container, protected from light and moisture. Do not freeze the solution. Follow standard aseptic techniques when preparing the intravesical dose, and discard any unused portion according to local hazardous waste regulations.

The drug is given by intravesical instillation. After catheterizing the bladder, the sterile solution is introduced and retained for a prescribed dwell time, usually one hour, before the patient voids. The procedure is performed under sterile conditions in a clinical setting.

Serious risks include severe chemical cystitis, systemic bone‑marrow suppression leading to neutropenia or anemia, renal toxicity, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, bleeding, or organ dysfunction during and after treatment.

Mitomycin Medac is contraindicated in patients with active urinary tract infections, severe renal impairment, known hypersensitivity to mitomycin or related compounds, pregnant or breastfeeding women, and those receiving other potent alkylating agents or pelvic radiation without appropriate clinical justification.